Virtual Library

Start Your Search

Kanghoon Lee



Author of

  • +

    MA01 - Oligometastatic Disease (ID 114)

    • Event: WCLC 2019
    • Type: Mini Oral Session
    • Track: Oligometastatic NSCLC
    • Presentations: 1
    • Now Available
    • +

      MA01.05 - Progress of Accompanying GGN Beyond Pulmonary Resection for Non-Small Cell Lung Cancer (Now Available) (ID 1525)

      10:30 - 12:00  |  Presenting Author(s): Kanghoon Lee

      • Abstract
      • Presentation
      • Slides

      Background

      The aim of this retrospective study was to review the natural course of synchronous ground-glass nodule (GGN), which was left after the curative resection of non-small cell lung cancer (NSCLC) in other lobe.

      Method

      Between 2008 and 2017, a prospectively collected retrospective data of 2276 patients who underwent curative resection for NSCLC was reviewed. Among them, GGN was detected in 126 patients beside resected lung. Defined by high-resolution computed tomography (HRCT) or thin-section of computed tomography (CT), twenty patients with nearly solid nodule or GGN with higher CT ratio (> 0.75) was excluded, thereafter the data of 98 patients (4.3%) was included in the study. Demographic data of patients including age, gender, and smoking history were collected for analysis. In addition, risk factor including characteristics of GGN, histopathology and staging of resected tumor, adjuvant treatment, and any other medical history were evaluated for risk factor analysis.

      Result

      Median duration of follow-up was 36 months (range; 11 – 120). The size of GGN has been decreased in 10 patients (10.2%), stationary 48 patients (50.0%), while an increasing in size of GGN was observed in 40 patients (40.8%). Among them, five patients were recommended reoperation (12.5%), and the other 35 patients were in clinical observation (87.5%). In mutivariate analysis, existence of solid component, smoking history, and multiple GGNs in one lobe were independent prognostic factor.

      table.png

      Conclusion

      During the follow-up, 40.8% of GGN showed a growth in size, emphasizing that patients with part-solid GGN and with smoking history should be in careful observation.

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P1.14 - Targeted Therapy (ID 182)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Targeted Therapy
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/08/2019, 09:45 - 18:00, Exhibit Hall
    • +

      P1.14-45 - Surgical Outcome of Non-Small Cell Lung Cancer with Clinical Single Zone N2 in Aortopulmonary Zone (LN#5 and LN#6) (Now Available) (ID 1550)

      09:45 - 18:00  |  Presenting Author(s): Kanghoon Lee

      • Abstract
      • Slides

      Background

      Current staging work-up methodology could not exactly reflect clinical nodal status of aortopulmonary zone (AP zone) without invasive diagnostic tools. The aim of the study is to evaluate the surgical outcome of single zone clinical N2 in AP zone (LN #5 or #6).

      Method

      Between 2009 and 2018, a retrospective data of 7488 patients was reviewed. Patients were included when only lymph nodes in AP zone was suspected to be metastasized based on the results of computed tomography (CT), positron emission tomography (PET-CT) and endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA). Patients were excluded when metastasis was detected by EBUS-TBNA in other mediastinal lymph node zones. Clinicopathologic variables such as pathologic subtype, differentiation and nodal status were evaluated to identify prognostic factors for survival rate and disease-free survival rate (DFS).

      Result

      Ninety-five patients were included, and median duration of follow-up was 35 months (IQR; 20 – 50). Eighty-four patients underwent upfront surgery, and their pathologic nodal staging was pN0 in 20 patients (23.8%), pN1 in 7 (8.3%), pN2a in 40 (47.6%) and pN2b in 17 (20.2%). Overall 5-year survival and 5-year DFS rate was 55.9% 54.5%, respectively. There was no survival difference between patients with pN0-1, pN2a and pN2b (p = 0.345, figure). Neither pathologic N2 nor N2b was not a risk factor for overall survival rate (p = 0.418, 0.159, respectively) and DFS (p = 0.606, 0.650, respectively). In univariate analysis, there was no other significant clinicopathologic factors for survival and DFS. Eleven patients with neoadjuvant treatment showed a similar 5-year survival rate (43.6%) compared with patients with upfront surgery.figure ver. 2.1.png

      Conclusion

      Current work-up without invasive tools for cN2a in AP zone showed relatively high false-positive rate (32.1%). However, surgical outcome of cN2a in aortopulmonary zone was comparable. Upfront surgery should be considered in highly selected patients.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.